181 related articles for article (PubMed ID: 20297875)
1. Evolving regulatory landscape with erythropoiesis-stimulating agents and impact on managed care.
Fatodu H
Am J Manag Care; 2010 Mar; 16 Suppl Issues():S74-9. PubMed ID: 20297875
[TBL] [Abstract][Full Text] [Related]
2. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
Singh AK
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
[TBL] [Abstract][Full Text] [Related]
3. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
[TBL] [Abstract][Full Text] [Related]
4. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
5. Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate.
Agarwal R
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1340-6. PubMed ID: 20448071
[TBL] [Abstract][Full Text] [Related]
6. Anemia and cardiovascular risk in the patient with kidney disease.
Fishbane S
Heart Fail Clin; 2008 Oct; 4(4):401-10. PubMed ID: 18760752
[TBL] [Abstract][Full Text] [Related]
7. The role of erythropoiesis-stimulating agents in the treatment of anemia.
Fishbane S
Am J Manag Care; 2010 Mar; 16 Suppl Issues():S67-73. PubMed ID: 20297874
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin in cancer patients.
Glaspy JA
Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
[TBL] [Abstract][Full Text] [Related]
9. Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Drug Saf; 2012 Nov; 11(6):923-31. PubMed ID: 22916722
[TBL] [Abstract][Full Text] [Related]
10. Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.
Doss S; Schiller B
Nephrol Nurs J; 2010; 37(6):617-26. PubMed ID: 21290916
[TBL] [Abstract][Full Text] [Related]
11. The Impact of the Risk Evaluation Mitigation Strategy for Erythropoiesis-Stimulating Agents on Their Use and the Incidence of Stroke in Medicare Subjects with Chemotherapy-Induced Anemia with Lung and/or Breast Cancers.
Hollingsworth K; Romney MC; Crawford A; McAna J
Popul Health Manag; 2016 Feb; 19(1):63-9. PubMed ID: 26102512
[TBL] [Abstract][Full Text] [Related]
12. Adverse consequences with use of erythropoiesis-stimulating agents in anemia prompt release of guidelines to ensure safe use and maximize benefit.
Dharmarajan TS; Widjaja D
Geriatrics; 2008 Jun; 63(6):13-29. PubMed ID: 18512996
[TBL] [Abstract][Full Text] [Related]
13. Tumor progression associated with erythropoiesis-stimulating agents.
Newland AM; Black CD
Ann Pharmacother; 2008 Dec; 42(12):1865-70. PubMed ID: 19017828
[TBL] [Abstract][Full Text] [Related]
14. [Role of renal anemia in progression of chronic kidney disease].
Racki S; Maleta I
Acta Med Croatica; 2009 Sep; 63 Suppl 1():33-7. PubMed ID: 20235353
[TBL] [Abstract][Full Text] [Related]
15. Erythropoiesis-stimulating agents in anemia: use and misuse.
Dharmarajan TS; Widjaja D
J Am Med Dir Assoc; 2009 Nov; 10(9):607-16. PubMed ID: 19883882
[TBL] [Abstract][Full Text] [Related]
16. Is nephrology more at ease than oncology with erythropoiesis-stimulating agents? Treatment guidelines and an update on benefits and risks.
Locatelli F; Gascón P
Oncologist; 2009; 14 Suppl 1():57-62. PubMed ID: 19762517
[TBL] [Abstract][Full Text] [Related]
17. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
Singh AK
Clin J Am Soc Nephrol; 2010 Apr; 5(4):553-6. PubMed ID: 20203166
[No Abstract] [Full Text] [Related]
18. Risk evaluation mitigation strategy: impact of application of the Food and Drug Adminstration's strategy on use of erythropoiesis-stimulating agents and transfusion in patients with chemotherapy-induced anaemia.
Hollingsworth K; Romney MC; Crawford A; McAna J
J Clin Pharm Ther; 2015 Jun; 40(3):299-303. PubMed ID: 25893427
[TBL] [Abstract][Full Text] [Related]
19. Erythropoiesis-stimulating agents and heart failure.
Lipšic E; van der Meer P; van Veldhuisen DJ
Cardiovasc Ther; 2011 Aug; 29(4):e52-9. PubMed ID: 20973926
[TBL] [Abstract][Full Text] [Related]
20. [Erythropoesis-stimulating agents: past, present and future].
Kes P; Basić-Jukić N
Acta Med Croatica; 2009 Sep; 63 Suppl 1():3-6. PubMed ID: 20235351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
